TB R&D Weekly Update: Podcast Interview with Anne Lenaerts

[wpaudio url=”/blog/media/podcasts/Anne_Lenaerts_Interview_edited-norm.mp3″ text=”Anne Lenaerts Interview” dl=”0″]

Listen to Anne Lenaerts Podcast

Summary: Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology. The WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010. In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies.

Additional TB R&D News:

REVIEW: The challenge of new drug discovery for tuberculosis

Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies

Progress in tuberculosis vaccine research

Race against time to develop new antibiotics

S. Korean Biotech Company Decodes Antibiotic Resistant Superbug form

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...